• Revenue (Q4 2024): $161 million, a 21% increase compared to Q4 2023.
• Revenue (Full Year 2024): $605 million, a 19% increase year-over-year.
• Gross Margin (Q4 2024): 79%.
• Gross Margin (Full Year 2024): 77%, up from 75% in 2023.
• Sales and Marketing Expenses (Q4 2024): $67 million.
• Sales and Marketing Expenses (Full Year 2024): $239 million.
• G&A Expenses (Q4 2024): $72 million.
• G&A Expenses (Full Year 2024): $190 million.
• R&D Expenses (Q4 2024): $51 million.
• R&D Expenses (Full Year 2024): $210 million.
• Net Loss (Q4 2024): $66 million or $0.61 per share.
• Net Loss (Full Year 2024): $169 million or $1.56 per share.
• Adjusted EBITDA (Q4 2024): $3 million, an increase of $34 million from Q4 2023.
• Adjusted EBITDA (Full Year 2024): $1 million, an increase of $107 million compared to last year.
• Cash and Cash Equivalents (End of 2024): $960 million.

• Warning! GuruFocus has detected 4 Warning Signs with NVCR.

Release Date: February 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• NovoCure Ltd (NASDAQ:NVCR) achieved FDA approval for the treatment of non-small cell lung cancer, expanding its market reach beyond glioblastoma.
• The company reported a 19% year-over-year increase in net revenue for 2024, reaching $605 million.
• Successful Phase 3 trial results in pancreatic cancer and brain metastases from non-small cell lung cancer were announced, indicating potential for further market expansion.
• NovoCure Ltd (NASDAQ:NVCR) grew its global active patient count to over 4,000, marking a 10% increase.
• The company has a strong cash position with $960 million in cash and cash equivalents, providing financial stability for future growth initiatives.

Negative Points

• NovoCure Ltd (NASDAQ:NVCR) reported a net loss of $169 million for the year, indicating ongoing financial challenges.
• The company faces headwinds to gross margin due to the rollout of new HFE arrays and the launch of the lung cancer indication.
• Reimbursement negotiations for the new lung cancer indication are ongoing, with material revenue expected to ramp up only in 2026.
• Sales and marketing expenses increased by 14% in the fourth quarter, reflecting higher costs associated with new product launches.
• The company anticipates a temporary decline in gross margins to the lower 70s due to increased costs associated with new product launches.

Q & A Highlights

Q: Can you provide more details on when and where we might see the PANOVA full data presentation, and what additional insights might be revealed compared to the top line disclosure? A: Unfortunately, we can't provide specific details yet, but we are targeting all major conferences in the spring. We will share more information once we have confirmed acceptance. These are important data, and we are eager to present them soon. - Ashley Cordova, CEO, and Nicolas Leupin, Chief Medical Officer

Q: What are your expectations for the trajectory of the lung cancer launch, and can you provide insights into physician and patient engagement? A: Our focus is on ensuring a strong positive first experience for physicians and patients, which builds confidence for future prescriptions. We are also working towards positive coverage policies with payers. We don't provide specific guidance, but we aim to build on the strong start and establish good relationships with practices and payers. - Frank Leonard, EVP and President, Novocure Oncology

Q: Can you elaborate on the improved US approval rates and their impact on revenue, and what should we expect for 2025? A: In 2024, growth from improved approval rates was $42 million, with $22 million from prior periods. We don't expect similar impacts going forward, as approval rates are at a level where there's not much room for improvement. Growth will align with Optune Gio active patient growth. - Christoph Brackmann, CFO

Q: What are the expectations for the METIS and PANOVA publications and filings, and is there any reason for the timing? A: We expect publications this year and are finalizing submissions. We are in active pre-submission discussions with the FDA, utilizing our breakthrough device designation for interactive review. The timing reflects our focus on thorough preparation. These indications represent significant opportunities for market expansion. - Ashley Cordova, CEO

Q: Regarding the lung cancer launch, are initial prescriptions mainly for PD-1-naive patients, and are patients receiving both docetaxel and PD-1 inhibitors? A: We are seeing patients receive both docetaxel and immune checkpoint inhibitors concurrently with Tumor Treating Fields. We are also seeing retreatment with ICI or continuation for patients who had ICI in the front line, indicating a good demographic mix. - Frank Leonard, EVP and President, Novocure Oncology

For the complete transcript of the earnings call, please refer to the full earnings call transcript.